Infections and organ transplantation: New challenges for prevention and treatment-a colloquium

Transplantation

Volumn 93, Issue SUPPL. 5, 2012, Pages

  Grossi, Paolo A ^a   Costa, Alessandro Nanni ^b   Fehily, Deirdre ^b   Blumberg, Emily A ^c   Kuehnert, Matthew J ^d   Fishman, Jay A ^e   Ison, Michael G ^f,g   Lattes, Roberta ^h   Kotton, Camille N ^e,i   Lilleri, Daniele ^j   Kabanova, Anne ^k   Lanzavecchia, Antonio ^k   Gerna, Giuseppi ^j   Razonable, Raymund R ^l   Comoli, Patrizia ^j   Zecca, Marco ^j   Basso, Sabrina ^j   Ginevri, Fabrizio ^m   Grossi, Alessandra ⁿ   Schena, Francesco P ^o   Rimola, Antoni ^p   Burra, Patrizia ^q   Martin, Elenora De ^q   Rodriguez Castro, Kryssia Isabel ^q   Fagiuoli, Stefano ^r   Pasulo, Luisa ^r   Bruno, Raffaele ^s   Andreone, Pietro ^t   Loggi, Elisabetta ^t   Arena, Fabio ^u   Maria Rossolini, Gian ^u   Sganga, Gabriele ^v   Cozza, Valerio ^w   more..

^a UNIVERSITY OF INSUBRIA   (Italy)

^b Italian National Transplant Centre   (Italy)

^c HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^d NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

^f NORTHWESTERN MEMORIAL HOSPITAL   (United States)

^g Division of Organ Transplantation   (United States)

^h Instituto de Nefrologia Buenos Aires ar   (Argentina)

ⁱ HARVARD MEDICAL SCHOOL   (United States)

^j FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^k INSTITUTE FOR RESEARCH IN BIOMEDICINE   (Switzerland)

^l MAYO CLINIC   (United States)

^m G GASLINI INSTITUTE   (Italy)

ⁿ UNIVERSITY OF LUGANO   (Switzerland)

^o UNIVERSITY OF BARI   (Italy)

^p HOSPITAL CLÍNIC   (Spain)

^q UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^r Gastroenterology and Liver Transplant Unit   (Italy)

^s UNIVERSITY OF PAVIA   (Italy)

^t UNIVERSITY OF BOLOGNA   (Italy)

^u UNIVERSITY OF SIENA   (Italy)

^v CATHOLIC UNIVERSITY   (Italy)

^w SAPIENZA UNIVERSITY OF ROME   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR DIPIVOXIL; ALEMTUZUMAB; ANTIVIRUS AGENT; CARBAPENEMASE; CIDOFOVIR; COLISTIN; CYTOMEGALOVIRUS VACCINE; ECHINOCANDIN; FLUCONAZOLE; FOSCARNET; FOSFOMYCIN; GANCICLOVIR; GENTAMICIN; HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIGEN; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENT; LAMIVUDINE; OKT 3; PEGINTERFERON; RIBAVIRIN; RIFAMPICIN; SULTAMICILLIN; TIGECYCLINE; VALGANCICLOVIR; VORICONAZOLE;

ACINETOBACTER INFECTION; ADOPTIVE IMMUNOTHERAPY; ALLOTRANSPLANTATION; ANTIBIOTIC THERAPY; ANTIBODY RESPONSE; ANTIVIRAL THERAPY; ARTICLE; ASIAN; ASPERGILLOSIS; ASYMPTOMATIC DISEASE; BACTERIAL INFECTION; CD4 LYMPHOCYTE COUNT; CLINICAL PRACTICE; CULTURAL ANTHROPOLOGY; CYTOMEGALOVIRUS INFECTION; DISEASE CONTROL; DISEASE TRANSMISSION; DRUG DOSE INCREASE; DRUG SUBSTITUTION; ENDOGENOUS RETROVIRUS; ENTEROBACTERIACEAE INFECTION; EPSTEIN BARR VIRUS INFECTION; ERADICATION THERAPY; ESCHERICHIA COLI INFECTION; EUROPEAN UNION; GOVERNMENT REGULATION; GRAFT RECIPIENT; HEALTH BEHAVIOR; HEALTH BELIEF; HEALTH CARE MANAGEMENT; HEALTH CARE POLICY; HEART TRANSPLANTATION; HEPATITIS C; HERPES VIRUS INFECTION; HIGH RISK PATIENT; HUMAN; HUMAN HERPESVIRUS 6; HUMAN HERPESVIRUS 6 INFECTION; HUMAN HERPESVIRUS 7; HUMAN HERPESVIRUS 7 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INFECTION COMPLICATION; INFECTION CONTROL; INFECTION PREVENTION; INFECTION RISK; INTERCULTURAL COMMUNICATION; INTERPERSONAL COMMUNICATION; ITALY; KIDNEY TRANSPLANTATION; KLEBSIELLA PNEUMONIAE INFECTION; LEFT VENTRICULAR ASSIST DEVICE; LIVER TRANSPLANTATION; LOW DRUG DOSE; LYMPHOPROLIFERATIVE DISEASE; MEDICAL TOURISM; MORTALITY; MYCOSIS; NUCLEIC ACID ANALYSIS; OPPORTUNISTIC INFECTION; OPTIMAL DRUG DOSE; ORGAN DONOR; ORGAN TRANSPLANTATION; PARASITOSIS; PATIENT ATTITUDE; PATIENT SAFETY; PORCINE ENDOGENOUS RETROVIRUS; POSTOPERATIVE PERIOD; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE; PRACTICE GUIDELINE; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PSEUDOMONAS INFECTION; PUBLIC HEALTH SERVICE; PUBLIC-PRIVATE PARTNERSHIP; QUALITY ADJUSTED LIFE YEAR; RISK ASSESSMENT; RISK MANAGEMENT; RISK REDUCTION; SOCIAL PSYCHOLOGY; SOLID ORGAN TRANSPLANTATION; SURGICAL INFECTION; SURGICAL RISK; TRANSPLANT TOURISM; TREATMENT CONTRAINDICATION; TREATMENT DURATION; TREATMENT RESPONSE; UNITED STATES; VIRUS DETECTION; VIRUS LOAD; WORLD HEALTH ORGANIZATION; XENOTRANSPLANTATION;

COMMUNICABLE DISEASES; DISEASE TRANSMISSION, INFECTIOUS; EUROPEAN UNION; HUMANS; NEOPLASMS; ORGAN TRANSPLANTATION; RISK ASSESSMENT; RISK FACTORS; TISSUE AND ORGAN PROCUREMENT; TISSUE DONORS; UNITED STATES;

EID: 84857879222     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3182481347     Document Type: Article

References (350)

1. Nanni Costa A, Grossi P, Porta E, et al. Measures taken to reduce the risk of West Nile virus transmission by transplantation in Italy. Euro Surveill 2008; 13: 16.
2. Capobianchi MR, Sambri V, Castilletti C, et al.; on behalf of the Italian Transplant Network. Retrospective screening of solid organ donors in Italy, 2009, reveals unpredicted circulation of West Nile virus. Euro Surveill 2010; 15: pii: 19648.
3. Villa E, Nanni Costa A. HIV-positive organs used for transplant in Italy due to human error. Euro Surveill 2007; 12: E070308.
4. http://uscode.house.gov/uscode-cgi/fastweb.exe? getdoc+uscview+t41t42+597+0++%28%29%20%20AND%20%28%2842%29%20ADJ%20USC%29%3ACIT E%20AND%20%28USC%20w%2F10%20%28273%29%29%3ACITE%20%20%20%20%20%20%20%20%20 http://www.gaonet.gov/special.pubs/organ/appendd.pdf. Accessed August 7, 2011.
5. http://ecfr.gpoaccess.gov/cgi/t/text/text-idx?c=ecfr&tpl=/ecfrbrowse/ Title42/42cfr121-main-02.tpl. Accessed August 7, 2011.
6. Rogers MF, Simonds RJ, Lawton KE, et al. Guidelines for preventing transmission of human immunodeficiency virus through transplantation of human tissues and organs. CDC MMWR Recommendations and Reports. 1994;43(RR-8):1. Availableat:http://www.cdc.gov/mmwr/preview/mmwrhtml/00031670.htm.
7. http://optn.transplant.hrsa.gov/policiesAndBylaws/policies.asp. Accessed August 7, 2011.
8. Ison MG, Hager J, Blumberg E, et al. Donor-derived transmission events in the United States: Data reviewed by the OPTN/UNOS Disease Transmission Advisory Committee. Am J Transplant 2009; 9: 1929.
9. http://www.cdc.gov/osels/ph-surveillance/nndss/phs/infdis2011.htm. Accessed August 7, 2011.
10. Zou S, Dodd RY, Stramer SL, et al.; for the Tissue Safety Study Group. Probability of viremia with HBV, HCV, HIV and HTLV among tissue donors in the United States. N Engl J Med 2004; 351: 751.
11. Ison MG, Green M, Covington S, et al. Discordant testing results Lessons learned. A report from the OPTN Ad Hoc Diseases Transmission Advisory Committee (DTAC). Vancouver, Canada, Infectious Diseases Society of America 2010. Available at: http://idsa.confex.com/idsa/2010/webprogram/Paper3055.html. Accessed August 7, 2011.
12. Blumberg E, Green M, Covington S, et al. Donor derived bacterial infections: Report from the Disease Transmission Advisory Committee (DTAC). Vancouver, Canada, Infectious Diseases Society of America 2010. http://idsa.confex.com/idsa/2010/webprogram/Paper3060.html. Accessed August 7, 2011.
13. FreemanRB,GiatrasI,FalagasME,et al.Outcomeoftransplantationoforgans procured from bacteremic donors. Transplantation 1999; 68: 1107.
14. Len O, Gavaldà J, Blanes M, et al. Donor infection and transmission to the recipient of a solid allograft. Am J Transplant 2008; 8: 2420.
15. Nalesnik MA, Woodle ES, DiMaio, JM, et al. Donor-transmitted malignancies in organ transplantation: Assessment of clinical risk. 2011; 11: 1140.
16. Iwamoto M, Jernigan DB, Guasch A, et al. Transmission of West Nile virus from an organ donor to four transplant recipients. N Engl J Med 2003; 348: 2196.
17. West Nile Virus transmission via organ transplantation and blood transfusion. Louisiana 2008. MMWR Morb Mortal Weekly Rep 2009; 58: 1263.
18. Fishman JA, Greenwald MA, Kuehnert MJ. Enhancing transplant safety: A new era in the microbiologic evaluation of organ donors? Am J Transplant 2007; 7: 2652.
19. Ison MG, Hager J, Blumberg E, et al. Donor-derived disease transmission events in the United States: Data reviewed by the OPTN/UNOS Disease Transmission Advisory Committee. Am J Transplant 2009; 9: 1929.
20. Centers for Disease Control and Prevention (CDC). Balamuthia mandrillaris transmitted through organ transplantation-Mississippi, 2009. MMWR Morb Mortal Wkly Rep 2010; 59: 1165.
21. Centers for Disease Control and Prevention (CDC). Notes from the field: Transplant-transmitted Balamuthia mandrillaris-Arizona, 2010. MMWR Morb Mortal Wkly Rep 2010; 59: 1182.
22. Fischer SA, Graham MB, Kuehnert MJ, et al.; for the LCMV in Transplant Recipients Investigation Team. Transmission of lymphocytic choriomeningitis virus by organ transplantation. N Eng J Med 2006; 354: 2235.
23. Ison MG, Llata E, Conover CS, et al.; HIV-HCV Transplantation Transmission Investigation Team. Transmission of human immunodeficiency virus and hepatitis C virus from an organ donor to four transplant recipients. Am J Transplant 2011; 11: 1218.
24. Centers for Disease Control and Prevention (CDC). HIV transmitted from a living organ donor-New York City, 2009. MMWR Morb Mortal Wkly Rep 2011; 60: 297 [also reprinted in JAMA 2011: 1647].
25. Centers for Disease Control and Prevention (CDC). Guidelines for preventing transmission of human immunodeficiency virus through transplantation of human tissue and organs. MMWR Morb Mortal Wkly Rep 1994; 43: RR-8.
26. Public Health Vigilance & Surveillance in Substances of Human Origin Project. http://www.sohovs.org/soho/. Accessed July 26, 2011.
27. Strong DM, Seem D, Taylor G, et al. Development of a transplantation transmission sentinel network to improve safety and traceability of organ and tissues. Cell Tissue Bank 2010; 11: 335.
28. Ellingson K, Seem D, Nowicki M, et al.; for the Organ Procurement Organization Nucleic Acids Testing Yield Project Team. Estimated risk of human immunodeficiency virus and hepatitis C virus infection among potential organ donors from 17 organ procurement organizations in the United States. Am J Transplant 2011; 11: 1201.
29. Humar A, Morris M, Blumberg E, et al. Nucleic acid testing (NAT) of organ donors: is the 'best' test the right test? A consensus conference report. Am J Transplant 2010; 10: 889.
30. Fischer SA, Graham MB, Kuehnert MJ, et al. Transmission of lymphocytic choriomeningitis virus by organ transplantation. N Engl J Med 2006; 354: 2235.
31. Fishman JA. Infection in solid-organ transplant recipients. N Engl J Med 2007; 357: 2601.
32. Grossi PA, Fishman JA; AST Infectious Disease Community of Practice. Donor-derived infections in solid organ transplant recipients. Am J Transplant 2009; 9(suppl 4): S19.
33. Ison MG, Nalesnik MA. An update on donor-derived disease transmission in organ transplantation. Am J Transplant 2011; 11: 1123.
34. Fishman JA. Rapporto dell'OMS sulla valutazione del programma nazionale trapianti in Italia. Trapianti 2008; 12: 37.
35. Grossi P, Strong DM. The role of testing in determining suitability of donors and tissues. In: WarwickRMFD, Brubaker SA, Eastlund T, eds. Tissue and cell donation: An essential guide. New York: Blackwell Publishing, 2009, pp 1009.
36. Fishman JA, Patience C. Xenotransplantation: Infectious risk revisited. Am J Transplant 2004; 4: 1383.
37. Pierson RN III, Dorling A, Ayares D, et al. Current status of xenotransplantation and prospects for clinical application. Xenotransplantation 2009; 16: 263.
38. Patience C, Takeuchi Y, Weiss RA. Infection of human cells by an endogenous retrovirus of pigs. Nat Med 1997; 3: 282.
39. Takeuchi Y, Patience C, Magre S, et al. Host range and interference studies of three classes of pig endogenous retrovirus. J Virol 1998; 72: 9986.
40. WoodJC, Quinn G, Suling KM, et al. Identification of exogenous forms of human-tropic porcine endogenous retrovirus in miniature swine. J Virol 2004; 78: 2494.
41. Martin SI, Wilkinson R, Fishman JA. Genomic presence of recombinant porcine endogenous retrovirus in transmitting miniature swine. Virol J 2006; 3: 91.
42. Fishman JA. Infection in solid-organ transplant recipients. N Engl J Med 2007; 357: 2601.
43. Wolfe RA, Roys EC, Merion RM. Trends in organ donation and transplantation in the United States, 1999-2008.AmJ Transplant 2010; 10(4 pt 2): 961.
44. Klein AS, Messersmith EE, Ratner LE, et al. Organ donation and utilization in the United States, 1999-2008. Am J Transplant 2010; 10(4 pt 2): 973.
45. Steering Committee of the Istanbul Summit. Organ trafficking and transplant tourism and commercialism: the Declaration of Istanbul. Lancet 2008; 372: 5.
46. World Health Organization. World Health Assembly Resolution 57.18, Human organ and tissue transplantation. May 22, 2004. Available at: http://www.who.int/gb/ebwha/pdf-files/WHA57/A57-R18-en.pdf. Accessed April 8, 2011.
47. Participants in the International Summit on Transplant Tourism and Organ Trafficking Convened by the Transplantation Society and International Society of Nephrology in Istanbul, Turkey, April 30-May 2, 2008. The Declaration of Istanbul on organ trafficking and transplant tourism. Transplantation 2008; 86: 1013.
48. Alghamdi SA, Nabi ZG, Alkhafaji DM, et al. Transplant tourism outcome: A single center experience. Transplantation 2010; 90: 184.
49. Canales MT, Kasiske BL, Rosenberg ME. Transplant tourism: Outcomes of United States residents who undergo kidney transplantation overseas. Transplantation 2006; 82: 1658.
50. Fujita M, Slingsby BT, Akabayashi A. Transplant tourism from Japan. Am J Bioeth 2010; 10: 24.
51. Ivanovski N, Masin J, Rambabova-Busljetic I, et al. The outcome of commercial kidney transplant tourism in Pakistan. Clin Transplant 2011; 25: 171.
52. Majid A, Al Khalidi L, Ahmed BQ, et al. Outcomes of kidney transplant tourism in children: A single center experience. Pediatr Nephrol 2010; 25: 155.
53. Merion RM, Barnes AD, Lin M, et al. Transplants in foreign countries among patients removed from the US transplant waiting list. Am J Transplant 2008; 8(4 pt 2): 988.
54. Shoham S, Hinestrosa F, Moore J Jr, et al. Invasive filamentous fungal infections associated with renal transplant tourism. Transpl Infect Dis 2010; 12: 371.
55. Allam N, Al Saghier M, El Sheikh Y, et al. Clinical outcomes for Saudi and Egyptian patients receiving deceased donor liver transplantation in China. Am J Transplant 2010; 10: 1834.
56. Delmonico FL. The hazards of transplant tourism. Clin J AmSoc Nephrol 2009; 4: 249.
57. Starzl T, Teperman L, Sutherland D, et al. Transplant tourism and unregulated black-market trafficking of organs. Am J Transplant 2009; 9: 1484.
58. Fischer SA, Avery RK. Screening of donor and recipient prior to solid organ transplantation. Am J Transplant 2009; 9(suppl 4): S7.
59. Ison MG, Hager J, Blumberg E, et al. Donor-derived disease transmission events in the United States: Data reviewed by the OPTN/UNOS Disease Transmission Advisory Committee. Am J Transplant 2009; 9: 1929.
60. Ison MG, Nalesnik MA. An update on donor-derived disease transmission in organ transplantation. Am J Transplant 2011; 11: 1123.
61. Centers for Disease Control and Prevention (CDC). HIV transmitted from a living organ donor-New York City, 2009. MMWR Morb Mortal Wkly Rep 2011; 60: 297.
62. Centers for Disease Control and Prevention (CDC). Potential transmission of viral hepatitis through use of stored blood vessels as conduits in organ transplantation-Pennsylvania, 2009. MMWR Morb Mortal Wkly Rep 2011; 60: 172.
63. Gill J, Madhira BR, Gjertson D, et al. Transplant tourism in the United States: A single-center experience. Clin J Am Soc Nephrol 2008; 3: 1820.
64. Polcari AJ, Hugen CM, Farooq AV, et al. Transplant tourism-A dangerous journey? Clin Transplant 2011; 25: 633.
65. Biggins SW. Supply and demand in transplant tourism: Disclosure duties of the transplant physician and our global transplant community. Liver Transpl 2010; 16: 246.
66. Schiano TD, Rhodes R. Transplant tourism. Curr Opin Organ Transplant 2010; 15: 245.
67. Schiano TD, Rhodes R. The dilemma and reality of transplant tourism: An ethical perspective for liver transplant programs. Liver Transpl 2010; 16: 113.
68. Barsoum RS. Parasitic infections in organ transplantation. Exp Clin Transplant 2004; 2: 258.
69. Antinori S, Cascio A, Parravicini C, et al. Leishmaniasis among organ transplant recipients. Lancet Infect Dis 2008; 8: 191.
70. VerouxM, Corona D, Giuffrida G, et al. Visceral leishmaniasis in the early post-transplant period after kidney transplantation: clinical features and therapeutic management. Transpl Infect Dis 2010; 12: 387.
71. Fischer L, Sterneck M, Claus M, et al. Transmission of malaria tertiana by multi-organ donation. Clin Transplant 1999; 13: 491.
72. Pandey D, Lee KH, Wong SY, et al. Malaria after living donor liver transplantation: Report of two cases. Hepatobiliary Pancreat Dis Int 2008; 7: 210.
73. Patel G, Arvelakis A, Sauter BV, et al. Strongyloides hyperinfection syndrome after intestinal transplantation. Transpl Infect Dis 2008; 10: 137.
74. Rodriguez-Hernandez MJ, Ruiz-Perez-Pipaon M, Cañas E, Bernal C, Gavilan F. Strongyloides stercoralis hyperinfection transmitted by liver allograft in a transplant recipient. Am J Transplant 2009;9(11):2637-40.
75. Brügemann J, Kampinga GA, Reizebos-Brilman A, et al. Two donorrelated infections transmitted in a heart transplant recipient: one common, the other a tropical surprise. J Heart Lung Transplant 2010;29 (12):1433-7.
76. Hamilton KW, ABT PL, Rosenbach Ma, et al. Donor -derived Strongyloides strecoralis infections in renal transplant recipients Transplantation. 2011; 91(9):1019-24.
77. Baden LR, Katz JT, Franck L, et al. Successful toxoplasmosis prophylaxis after orthotopic cardiac transplantation with trimethoprimsulfamethoxazole. Transplantation 2003; 75: 339.
78. Munoz P, Arencibia J, Rodriguez C, et al. Trimethoprim-sulfamethoxazole as toxoplasmosis prophylaxis for heart transplant recipients. Clin Infect Dis 2003; 36: 932; author reply 3.
79. Baran DA, Alwarshetty MM, Alvi S, et al. Is toxoplasmosis prophylaxis necessary in cardiac transplantation? Long-term follow-up at two transplant centers. J Heart Lung Transplant 2006; 25: 1380.
80. Vazquez MC, Riarte A, Pattin M, et al. Chagas' disease can be transmitted through kidney transplantation. Transplant Proc 1993; 25: 3259.
81. Barcán L, Luna C, Clara L, et al Transmission of T. cruzi infection via liver transplantation to a nonreactive recipient for Chagas' disease. Liver Transpl 2005; 11: 1112.
82. D'Albuquerque LA, Gonzalez AM, Filho HL, et al. Liver transplantation from deceased donors serologically positive for Chagas disease. Am J Transplant 2007; 7: 680.
83. Chagas Disease Argentine collaborative Transplant Consortium, Casadei D. Chagas' disease and solid organ transplantation. Transpl Proc 2010; 42: 3354.
84. Riarte A, Luna C, Sabatiello R, et al. Chagas' disease in patients with kidney transplants: 7 years of experience 1989-1996. Clin Infect Dis 1999; 29: 561.
85. Centers for Disease Control and Prevention. Chagas disease after organ transplantation-Los Angeles, California, 2006. MMWR Morb Mortal Wkly Rep 2006; 55: 798.
86. Centers for Disease Control and Prevention. Chagas disease after organ transplantation-United States, 2001. JAMA 2002; 287: 1795.
87. Kotton CN, Kumar D, Caliendo A, et al. International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation 2010; 89: 779.
88. Humar A, Snydman D. Cytomegalovirus in solid organ transplant recipients. Am J Transplant 2009; 9(suppl 4): S78.
89. Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Working Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 2009; 9(suppl 3): S1.
90. Fishman JA. Infection in solid-organ transplant recipients. N Engl J Med 2007; 357: 2601.
91. Hodson EM, Jones CA, Webster AC, et al. Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solidorgan transplants: A systematic review of randomised controlled trials. Lancet 2005; 365: 2105.
92. Kliem V, Fricke L, Wollbrink T, et al. Improvement in long-term renal graft survival due to CMV prophylaxis with oral ganciclovir: Results of a randomized clinical trial. Am J Transplant 2008; 8: 975.
93. Sagedal S, Hartmann A, Nordal KP, et al. Impact of early cytomegalovirus infection and disease on long-term recipient and kidney graft survival. Kidney Int 2004; 66: 329.
94. Asberg A, Humar A, Rollag H, et al. Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2007; 7: 2106.
95. McGavin JK, Goa KL. Ganciclovir: An update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients. Drugs 2001; 61: 1153.
96. Emery VC, Griffiths PD. Prediction of cytomegalovirus load and resistance patterns after antiviral chemotherapy. Proc Natl Acad Sci USA 2000; 97: 8039.
97. Chou SW. Cytomegalovirus drug resistance and clinical implications. Transpl Infect Dis 2001; 3(suppl 2): 20.
98. Sia IG, Wilson JA, Groettum CM, et al. Cytomegalovirus (CMV) DNA load predicts relapsing CMV infection after solid organ transplantation. J Infect Dis 2000; 181: 717.
99. Asberg A, Humar A, Jardine AG, et al. Long-term outcomes of CMV disease treatment with valganciclovir versus IV ganciclovir in solid organ transplant recipients. Am J Transplant 2009; 9: 1205.
100. Boeckh M, Nichols WG. Immunosuppressive effects of beta-herpesviruses. Herpes 2003; 10: 12.
101. Product Monograph Valcyte®. Swiss, Hoffmann-La Roche Limited, 2009.
102. Vaudry W, Ettenger R, Jara P, et al.;Valcyte WV16726 Study Group. Valganciclovir dosing according to body surface area and renal function in pediatric solid organ transplant recipients.AmJ Transplant 2009; 9: 636.
103. Hahn G, Revello MG, Patrone M, et al. Human cytomegalovirus UL131-128 genes are indispensable for virus growth in endothelial cells and virus transfer to leukocytes. J Virol 2004; 78: 10023.
104. Ryckman BJ, Rainish BL, Chase MC, et al. Characterization of the human cytomegalovirus gH/gL/UL128-131 complex that mediates entry into epithelial and endothelial cells. J Virol 2008; 82: 60.
105. Ryckman BJ, Chase MC, Johnson DC. Human cytomegalovirus TR strain glycoprotein O acts as a chaperone promoting gH/gL incorporation into virions but is not present in virions. J Virol 2010; 84: 2597.
106. Macagno A, Bernasconi NL, Vanzetta F, et al. Isolation of human monoclonal antibodies that potently neutralize human cytomegalovirus infection by targeting different epitopes on the gH/gL/UL128-131A complex. J Virol 2010; 84: 1005.
107. Zerr DM, Meier AS, Selke SS, et al. A population-based study of primary human herpesvirus 6 infection. N Engl J Med 2005; 352: 768.
108. Razonable RR, Paya CV. The impact of human herpesvirus-6 and -7 infection on the outcome of liver transplantation. Liver Transpl 2002; 8: 651.
109. Clark DA, Nacheva EP, Leong HN, et al. Transmission of integrated human herpesvirus 6 through stem cell transplantation: Implications for laboratory diagnosis. J Infect Dis 2006; 193: 912.
110. Jacobs U, Ferber J, Klehr HU. Severe allograft dysfunction after OKT3 induced human herpes virus-6 reactivation. Transplant Proc 1994; 26: 3121.
111. Peleg AY, Husain S, Kwak EJ, et al. Opportunistic infections in 547 organ transplant recipients receiving alemtuzumab, a humanized monoclonal CD-52 antibody. Clin Infect Dis 2007; 44: 204.
112. Humar A, Kumar D, Caliendo AM, et al. Clinical impact of human herpesvirus 6 infection after liver transplantation. Transplantation 2002; 73: 599.
113. Singh N, Carrigan DR, Gayowski T, et al. Variant B human herpesvirus-6 associated febrile dermatosis with thrombocytopenia and encephalopathy in a liver transplant recipient. Transplantation 1995; 60: 1355.
114. Potenza L, Luppi M, Barozzi P, et al. HHV-6A in syncytial giant-cell hepatitis. N Engl J Med 2008; 359: 593.
115. Randhawa PS, Jenkins FJ, Nalesnik MA, et al. Herpesvirus 6 variant A infection after heart transplantation with giant cell transformation in bile ductular and gastroduodenal epithelium. Am J Surg Pathol 1997; 21: 847.
116. Lamoth F, Jayet PY, Aubert JD, et al. Case report: Human herpesvirus 6 reactivation associated with colitis in a lung transplant recipient. J Med Virol 2008; 80: 1804.
117. Nash PJ, Avery RK, Tang WH, et al. Encephalitis owing to human herpesvirus-6 after cardiac transplant. Am J Transplant 2004; 4: 1200.
118. Anton A, Cervera C, Pumarola T, et al. Human herpesvirus 7 primary infection in kidney transplant recipients. Transplantation 2008; 85: 298.
119. Razonable RR, Rivero A, Brown RA, et al. Detection of simultaneous beta-herpesvirus infections in clinical syndromes due to defined cytomegalovirus infection. Clin Transplant 2003; 17: 114.
120. Ward KN, White RP, Mackinnon S, et al. Human herpesvirus-7 infection of the CNS with acute myelitis in an adult bone marrow recipient. Bone Marrow Transplant 2002; 30: 983.
121. Mendez JC, Dockrell DH, Espy MJ, et al. Human beta-herpesvirus interactions in solid organ transplant recipients. J Infect Dis 2001; 183: 179.
122. Dockrell DH, Mendez JC, Jones M, et al. Human herpesvirus 6 seronegativity before transplantation predicts the occurrence of fungal infection in liver transplant recipients. Transplantation 1999; 67: 399.
123. Singh N, Husain S, Carrigan DR, et al. Impact of human herpesvirus-6 on the frequency and severity of recurrent hepatitis C virus hepatitis in liver transplant recipients. Clin Transplant 2002; 16: 92.
124. Griffiths PD, Ait-Khaled M, Bearcroft CP, et al. Human herpesviruses 6 and 7 as potential pathogens after liver transplant: Prospective comparison with the effect of cytomegalovirus. J Med Virol 1999; 59: 496.
125. Jacobs F, Knoop C, Brancart F, et al. Human herpesvirus-6 infection after lung and heart-lung transplantation: A prospective longitudinal study. Transplantation 2003; 75: 1996.
126. Razonable RR, Lautenschlager I. Impact of human herpes virus 6 in liver transplantation. World J Hepatol; 2: 345.
127. Razonable RR, Zerr DM. HHV-6, HHV-7 and HHV-8 in solid organ transplant recipients. Am J Transplant 2009; 9(suppl 4): S97.
128. Lee SO, Brown RA, Eid AJ, et al. Chromosomally integrated human herpesvirus-6 in kidney transplant recipients. Nephrol Dial Transplant 2011; 26: 2391.
129. Green M. Management of Epstein-Barr virus-induced post-transplant lymphoproliferative disease in recipients of solid organ transplantation. Am J Transplant 2001; 1: 103.
130. Opelz G, Dohler B. Lymphomas after solid organ transplantation: A collaborative transplant study report. Am J Transplant 2003; 4: 222.
131. Cohen JI. Epstein-Barr virus infection. N Engl J Med 2000; 343: 481.
132. Thorley-Lawson DA, Gross A. Persistence of the Epstein-Barr virus and the origins of associated lymphomas. N Engl J Med 2004; 350: 1328.
133. Rickinson AB, Moss DJ. Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection. Annu Rev Immunol 1997; 15: 405.
134. Merlo A, Turrini R, Dolcetti R, et al. The interplay between EBV and the immune system: A rationale for adoptive cell therapy of EBV-related disorders. Haematologica 201095:1769.
135. Dharnidharka VR, Harmon WE. Management of pediatric postrenal transplantation infections. Semin Nephrol 2001; 21: 521.
136. Gottschalk S, Rooney CM, Heslop HE. Post-transplant lymphoproliferative disorders. Annu Rev Med 2005; 56: 29.
137. Baldanti F, Grossi P, Furione M, et al. High levels of Epstein-Barr virus DNA in blood of solid-organ transplant recipients and their value in predicting posttransplant lymphoproliferative disorders. J Clin Microbiol 2000; 38: 613.
138. Rowe DT, Webber S, Schauer EM, et al. Epstein-Barr virus load monitoring: Its role in the prevention and management of posttransplant lymphoproliferative disease. Transpl Infect Dis 2001; 3: 79.
139. Yang J, Tao Q, Flinn IW, et al. Characterization of Epstein-Barr virusinfected B cells in patients with posttransplantation lymphoproliferative disease: Disappearance after rituximab therapy does not predict clinical response. Blood 2000; 96: 4055.
140. Comoli P, Rooney CM. Treatment of Epstein-Barr virus infections. In: Jenson HB, Tselis A eds. Epstein-Barr virus. New York: Taylor & Francis 2006, pp 351.
141. + T-cell restoration. Blood 2002; 100: 2341.
142. Rooney CM, Smith CA, Ng CYC, et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 1998; 92: 1549.
143. Khanna R, Bell S, Sherritt M, et al. Activation and adoptive transfer of Epstein-Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease. Proc Natl Acad Sci USA 1999; 96: 10391.
144. Comoli P, Labirio M, Basso S, et al. Infusion of autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for prevention of EBV- related lymphoproliferative disorder in solid organ transplant recipients with evidence of active virus replication. Blood 2002; 99: 2592.
145. Rooney CM, Smith CA, Ng CY, et al. Use of gene-modified virusspecific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet 1995; 345: 9.
146. HaqueT,WilkieGM,TaylorC,et al.Treatmentof Epstein-Barr-virus-positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells. Lancet 2002; 360: 436.
147. Comoli P, Maccario R, Locatelli F, et al. Treatment of EBV-related post-renal transplant lymphoproliferative disease with a tailored regimen including EBV-specific T cells. Am J Transplant 2005; 5: 1415.
148. Savoldo B, Goss J, Hammer M, et al. Treatment of solid organ transplant recipients with autologous Epstein-Barr virus-specific cytotoxic T lymphocyte (CTL). Blood 2006; 108: 2942.
149. Sherritt MA, Bharadwaj M, Burrows JM, et al. Reconstitution of the latent T-lymphocyte response to Epstein-Barr virus is coincident with longterm recovery from posttransplant lymphoma after adoptive immunotherapy. Transplantation 2003; 75: 1556.
150. Haque T, Wilkie GM, Jones MM, et al. Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: Results of a phase 2 multicenter clinical trial. Blood 2007; 110: 1123.
151. Cobbold M, Khan N, Pourgheysari B, et al. Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers. J Exp Med 2005; 202: 379.
152. + T-cell lines for adoptive transfer into recipients of allogeneic stem cell transplantation. Blood 2004; 103: 3565.
153. Popescu I, Macedo C, Zeevi A, et al. Ex vivo priming of naïve T cells into EBV-specific Th1/Tc1 effector cells by mature autologous DC loaded with apoptotic/necrotic LCL. Am J Transplant 2003; 3: 1369.
154. + cytotoxic T cells from virus naive individuals. J Immunol 2002; 168: 909.
155. + T cells endowed with strong cytotoxic function from T cells of EBV-seronegative children. Am J Transplant 2006; 6: 2169.
156. De Angelis B, Dotti G, Quintarelli C, et al. Generation of Epstein-Barr virus-specific cytotoxic T lymphocytes resistant to the immunosuppressive drug tacrolimus (FK506). Blood 2009; 114: 4784.
157. Brewin J, Mancao C, Straathof K, et al. Generation of EBV-specific cytotoxic T-cells that are resistant to calcineurin inhibitors for the treatment of posttransplant lymphoproliferative disease. Blood 2009; 114: 4792.
158. Bollard CM, Rossig C, Calonge MJ, et al. Adapting a transforming growth factor β-related tumor protection strategy to enhance antitumor immunity. Blood 2002; 99: 3179.
159. Holton R. Globalization's cultural consequences. Ann Am Acad Polit Soc Sci 2000; 570: 140.
160. Woodman J. Patients Beyond Borders: Everybody's Guide to Affordable, World-Class Medical Travel, Healthy Travel Media. 2008.
161. Betancourt JR, Green AR, Carrillo JE. Ananeh-Firempong O. Defining cultural competence: A practical framework for addressing racial/ethnic disparities in health and health care, Public Health Rep 2003 Jul Aug; 118: 293-302. (Pubitemid 36828331)
162. International Organization for Migration (IOM). Developing a Public Health Workforce for Addressing Migrant Health Needs in Europe. 2006. Avialable at: http://www.migrant-health-europe.org/files/Health-workforce-paper- WebsiteFINAL%2821-10%29.pdf. Accessed January 2011.
163. Poglia E. Intercultural communication: An interdisciplinary model for institutional contexts. Studies Comm Sci 2006; 6: 103.
164. Stewart MA. Effective physician-patient communication and health outcomes: A review. Can Med Assoc J 1995; 152: 1423.
165. YS Wong S, Lee A. Communication skills and doctor-patient relationship. Med Bull 2006; 11: 7.
166. Lee S-G, Asian contribution to living donor liver transplantation. J Gastroenterol Hepatol 2006; 21: 572.
167. Gruessner RWG, Benedetti E, Kiuchi T. and Kamei H. The Asian Perspective, East Asia, in Living Donor Transplantation. New York: McGraw Hill Professional 2008, pp. 23.
168. Lam WA, McCullough MB. Influence of religious and spiritual values on the willingness of Chinese-Americans to donate organs for transplantation. Clin Transplant 2000; 14: 449.
169. Tuttle-Newhall JE, Krishnan SM, Levy MF, et al. Organ donation and utilization in the United States: 1998-2007. Am J Transplant 2009; 9(4 pt 2): 879.
170. Raza M, Hedayat KM. Some sociocultural aspects of cadaver organ donation: Recent rulings from Iran. Transplant Proc 2004; 36: 2888.
171. Siminoff LA, Burant C, Youngner SJ. Death and organ procurement: Public beliefs and attitudes. Kennedy Inst Ethics J 2004; 14: 217.
172. Hattori K, McCubbin MA, Ishida DN. Concept analysis of good death in the Japanese community. J Nurs Scholarsh 2006; 38: 165.
173. Kim JR, Elliott D, Hyde C. Korean nurses' perspectives of organ donation and transplantation: A review. Transplant Nurses J 2002; 11: 20.
174. Emiko O-T. Brain death and organ transplantation: Cultural bases of medical technology. Curr Anthropol 1994; 35: 233.
175. Bowman KW, Richard SA. Culture, brain death, and transplantation. Prog Transplant 2003; 13: 211.
176. Stoeckle ML. Attitudes of critical care nurses toward organ donation. Dimens Crit Care Nurs 1990; 9: 354.
177. Hoyer WD, MacInnis DJ. Consumer Behavior. Boston: Francesco, Houghton Mifflin Company 1997.
178. Inglehart R, Welzel C. Modernization, cultural change and democracy. New York: Cambridge University Press 2005; based on the World Values Surveys. Available at: see www.worldvaluessurvey.org.
179. Kurtz Lester R. Gods in the global village: The world's religions in sociological perspective. Thousand Oaks: Pine Forge Press 2007.
180. Kim JR, Elliott D, Hyde C. The Influence of sociocultural factors on organ donation and transplantation in Korea: Findings from key informant interviews. J Transcult Nurs 2004; 15: 147.
181. Martín JM. Influencia de los conceptos religiosos ante las donaciones de ó rganos. Indivisa, Boletin de estudios e investigación, No. 3. 2002. Available at: http://redalyc.uaemex.mx/ redalyc/src/inicio/ArtPdfRed.jsp?iCve=77100308. ISSN 1579-3141. Accessed February 2011.
182. Oliver M, Woywodt A, Ahmed A, et al. Organ donation, transplantation and religion. Nephrol Dial Transplant 2011; 26: 437.
183. Song RL, Cui XH, Gao Z, et al. Brain death and organ transplant legislation: Analysis of 969 respondents by classroom questionnaire. Hepatobiliary Pancreat Dis Int 2009; 8: 483.
184. The Transplantation Society. Japanese parliament approved a new brain death law. 2009; 6. Available at: http://www.tts.org/images/stories/pdfs/
185. Shan J. Nation to recognize brain death, China Daily, August 3, 2008. Available at: http://www.chinadaily.com.cn/china/2008npc/2008-03/ 08/content-6519535.htm. Accessed February 2011.
186. Lock M. Cultural aspects of organ donation and transplantation. Transplant Proc 1999; 31: 1345.
187. Chung CK, Ng CW, Li JY, et al. Attitudes, knowledge, and actions with regard to organ donation among Hong Kong medical students. Hong Kong Med J 2008; 14: 278.
188. Geert H. The business of international business is culture. Int Bus Rev 1994; 3: 1.
189. Zakaria F. Culture is destiny-A conversation with Lee Kuan Yew. Foreign Aff 1994; 73: 109.
190. Thompson TL, Robinson JD, Kenny RW. Gender differences in family communication about organ donation. Sex Roles 2003; 49: 587.
191. Pearson JC, West RL, Turner LH. Gender and communication [ed. 3]. New York: Brown and Benchmark 1995.
192. Ronald I. Modernization and postmodernization: Cultural, economic, and political change in 43 societies. Princeton: Princeton University Press 1997.
193. Kramsch CJ. Language and culture. Oxford: Oxford University Press 2008.
194. Radecki CM, Jaccard J. Psychological aspects of organ donation: A critical review and synthesis of individual and next-of-kin donation decisions. Health Psychol 1997; 16: 183.
195. Park HS, Smith SW, Yun D. Ethnic differences in intention to enroll in a State organ donor registry and intention to talk with family about organ donation. Health Commun 2009; 24: 647.
196. Núñez GR. Culture, demographics, and critical care issues: An overview. Crit Care Clin 2003; 19: 619.
197. Asai A, Kadooka Y, Aizawa K. Arguments against promoting organ transplants from brain-dead donors, and views of contemporary Japanese on life and death. Bioethics (in press).
198. Cialdini R. Influence: Science and practice. Boston: Allyn&Bacon 2001.
199. Turner JC. Rediscovering the social group: A self-categorization theory. Oxford, Blackwell 1987.
200. Suh E, Diener E, Oishi S, et al. The shifting basis of life satisfaction judgments across cultures: Emotions versus norms. J Pers Soc Psychol 1998; 74: 482.
201. Muto K. Organ transplantation as a family issue: living liver donors in Japan. Int J Japn Sociol 2010; 19: 35.
202. Yehieli M, Grey MA. Health matters: A pocket guide to working with diverse cultures and underserved populations. Boston: Intercultural Press 2005.
203. Galanti G-A, Caring for patients from different cultures. Philadelphia: University of Pennsylvania Press 2008.
204. Campistol JM, Boletis IN, Dantal J, et al. Chronic allograft nephropathy-A clinical syndrome: Early detection and the potential role of proliferation signal inhibitors. Clin Transplant 2009; 23: 769.
205. Segoloni G, Stefoni S, Rigotti P, et al. Immunosoppressive therapy and risk of post-transplant malignancies after kidney transplantation: Italian multicentric study. Am J Transplant 2011; 11(52): 509.
206. Moore J, Middleton L, Cockwell P, et al. Calcineurin inhibitor sparing with mycophenolate in kidney transplantation: A systematic review and meta-analysis. Transplantation 2009; 87: 591.
207. Flechner SM, Kurian SM, Solez K, et al. De novo kidney transplantation without use of calcineurin inhibitors preserves renal structure and function at two years. Am J Transplant 2004; 4: 1776.
208. Oberbauer R, Segoloni G, Campistol JM, et al.; Rapamune Maintenance Regimen Study Group. Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48 months after transplantation. Transpl Int 2005; 18: 22.
209. Eris J. Clinical experience with everolimus (Certican) in young renal transplant recipients.Transplantation 2005; 79: S89.
210. Kreis H, Oberbauer R, Campistol JM, et al.; Rapamune Maintenance Regimen Trial. Long-term benefits with sirolimus-based therapy after early cyclosporine withdrawal. J Am Soc Nephrol 2004; 15: 809.
211. Schena FP, Pascoe MD, Alberu J, et al.; Sirolimus CONVERT Trial Study Group. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation 2009; 87: 233.
212. Alberú J, Pascoe MD, Campistol MJ, et al. Lower malignancy rates in renal allograft recipients converted to sirolimus-based, calcineurin inhibitor free immunotherapy: 24-month results from the CONVERT Trial. Transplantation 2011; 92: 303.
213. Tedesco Silva H Jr, Cibrik D, Johnston T, et al. Everolimus plus reduced exposure CsA versus mycophenolic acid plus standard-exposure CsA in renal-transplant recipients.AmJ Transplant 2010; 10: 1401.
214. Martínez E, Milinkovic A, Buira E, et al. Incidence and causes of death in HIV-infected persons receiving highly active antiretroviral therapy compared with estimates for the general population of similar age and from the same geographical area. HIV Med 2007; 8: 251.
215. Neff GW, Bonham A, Tzakis AG, et al. Orthotopic liver transplantation in patients with human immunodeficiency virus and end-stage liver disease. Liver Transpl 2003; 9: 239.
216. Grossi P, Gabbrielli F, De Cillia C, et al. The Italian experience of liver transplantation in HIV-infected individuals. J Hepatol 2008; 48(suppl 2): S49.
217. Fung J, Eghtesad B, Patel-Tom K, et al. Liver transplantation in patients with HIV infection. Liver Transplant;2004: 10(suppl 2.): S39.
218. Ragni MV, Belle SH, Im K, et al. Survival of human immunodeficiency virus-infected liver transplant recipients. J Infect Dis 2003; 188: 1412.
219. Schreibman I, Gaynor JJ, Jayaweera D, et al. Outcomes after orthotopic liver transplantation in 15 HIV-infected patients. Transplantation 2007; 84: 697.
220. Vennarecci G, Ettore GM, Antonini M, et al. Liver transplantation in HIV-positive patients. Transplant Proc 2007; 39: 1936.
221. Roland ME, Barin B, Carlson L, et al. HIV-infected liver and kidney transplant recipients: 1-and 3- year outcomes.AmJ Transplant 2008; 8: 355.
222. Mindikoglu AL, Regev A, Magder LS. Impact of human immunodeficiency virus on survival after liver transplantation: Analysis of United Network for Organ Sharing database. Transplantation 2008; 85: 359.
223. Baccarani U, Adani GL, Tavio M. et al. Liver transplantation in HIV positive patients: Comparison with a matched HIV negative population. Am J Transplant 2009; 9(suppl 2): 260.
224. Duclos-Vallée JC, Féray C, Sebagh M, et al. Survival and recurrence of hepatitis C after liver transplantation in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatology 2008; 47: 407.
225. Norris S, Taylor C, Muiesan P, et al. Outcomes of liver transplantation in HIV-infected individuals: The impact of HCV and HBV infection. Liver Transplant 2004; 10: 1271.
226. De Vera ME, Dvorchik I, Tom K, et al. Survival of liver transplant patients coinfected with HIV and HCV is adversely impacted by recurrent hepatitis C. Am J Transplant 2006; 6: 2983.
227. Joshi D, Aluvihare V, Belgaumkar A, et al. Liver transplantation for HIV: Long term outcomes from the UK.AmJ Transplant 2009; 9(suppl 2): S74.
228. Terrault NA, Carter JT, Carlson L, et al. Outcome of patients with hepatitis B virus and human immunodeficiency virus infections referred for liver transplantation. Liver Transplant 2006; 12: 801.
229. Tateo M, Roque-Afonso A-M, Antonini TM, et al. Long-term follow up of liver transplanted HIV/ hepatitis B virus coinfected patients: Perfect control of hepatitis B virus replication and absence of mitochondrial toxicity. AIDS 2009; 23: 1069.
230. Coffin CS, Berg CL, Dove LM, et al. Survival and risk of Hepatitis B virus (HBV) recurrence in HIV-HBV coinfected liver transplant recipients: Preliminary findings form the HIV-TR study. Hepatology 2007; 46: 245A.
231. Vojcik K, Vogel M, Voigt E, et al. Antiviral therapy for hepatitis C recurrence after liver transplantation in HIV-infected patients: Outcome in the Bonn cohort. AIDS 2007; 21: 1363.
232. Castells L, Esteban JI, Bilbao I, et al. Early antiviral treatment of hepatitis C virus recurrence after liver transplantation in HIV-infected patients. Antivir Ther 2006; 11: 1061.
233. Berenguer M. Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin. J Hepatol 2008; 49: 274.
234. Roland ME, Stock PG. Solid organ transplantation is a reality for patients with HIV infection. Curr HIV/AIDS Rep 2006; 3: 132.
235. O'Grady J, Taylor C, Brook G. Guidelines for liver transplantation in patients with HIV infection (2005). HIV Med 2005; 6(suppl 2): 149.
236. Grossi P, Tumietto F, Costigliola P, et al. Liver transplantation in HIVinfected individuals: Results of the Italian National Program. Transpl Int 2005; 18(suppl 1): 11.
237. Miró JM, Laguno M, Moreno A, et al. the Hospital Clinic OLT in HIV Working Group. Management of end stage liver disease (ESLD): What is the current role of orthotopic liver transplantation (OLT)? J Hepatol 2006; 44(suppl 1): S140.
238. Subramanian A, Sulkowski M, Barin B, et al. MELD score is an important predictor of pretransplantation mortality in HIV-infected liver transplant candidates. Gastroenterology 2010; 138: 159.
239. Vibert E, Duclos-Vallée JC, Ghigna MR, et al. Liver transplantation for hepatocellular carcinoma: The impact of human immunodeficiency virus infection. Hepatology 2011; 53: 475.
240. Frassetto LA, Browne M, Cheng A, et al. Immunosuppressant pharmacokinetics and dosing modifications in HIV-1 infected liver and kidney transplant recipients. Am J Transplant 2007; 7: 2816.
241. Teicher E, Laurence I, Bonhomme-Faivre L, et al. Effect of highly active antiretroviral therapy on tacrolimus pharmacokinetics in hepatitis C virus and HIV co-Infected liver transplant recipients in the ANRS HC-08 Study. Clin Pharmacokinet 2007; 46: 941.
242. Lewden C, Chene G, Morlat P, et al. HIV-infected adults with a CD4 cell count greater than 500 cells/mm3 on long-term combination antiretroviral therapy reach same mortality rates as the general population. J Acquir Immune Defic Syndr 2007; 46: 72.
243. Bhaskaran K, Hamouda O, Sannes M, et al. Changes in the risk of death after HIV seroconversion compared with mortality in the general population. JAMA 2008; 300: 51.
244. Sackoff JE, Hanna DB, Pfeiffer MR, et al. Causes of death among persons with AIDS in the era of highly active antiretroviral therapy: New York City. Ann Intern Med 2006; 145: 397.
245. Zareba KM, Lipshultz SE. Cardiovascular complications in patients with HIV infection. Curr Infect Dis Rep 2003; 5: 513.
246. Rerkpattanapipat P, Wongpraparut N, Jacobs LE, et al. Cardiac manifestations of acquired immunodeficiency syndrome. Arch Intern Med 2000; 160: 602.
247. Aberg J. Cardiovascular complications in HIV management: Past, present, and future. J Acquir Immune Defic Syndr 2009; 50: 54.
248. Currier JS. Update on cardiovascular complications in HIV infection. Top HIV Med 2009; 17: 98.
249. Worm SW, Sabin C, Weber R, et al. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: The data collection on adverse events of anti-HIV drugs (D:A:D) study. J Infect Dis 2010; 201: 318.
250. Mehta, NJ, Khan, IA, Mehta, RN, et al. HIV-related pulmonary hypertension: Analytic review of 131 cases. Chest 2000; 118: 1133.
251. Humbert, M, Sitbon, O, Chaouat, A, et al. Pulmonary arterial hypertension in France: Results from a national registry. Am J Respir Crit Care Med 2006; 173: 1023.
252. Petrosillo, N, Chinello, P, Cicalini, S. Pulmonary hypertension in individuals with HIV infection. AIDS 2006; 20: 2128.
253. Calabrese LH, Albrecht M, Young J, et al. Successful cardiac transplantation in an HIV-1-infected patient with advanced disease. N Engl J Med 2003; 348: 2323.
254. Bisleri G, Morgan JA, Deng MC, et al. Should HIV-positive recipients undergo heart transplantation? J Thorac Cardiovasc Surg 2003; 126: 1639.
255. Uriel N, Jorde UP, Cotarlan V, et al. Heart transplantation in human immunodeficiency virus-positive patients. J Heart Lung Transplant 2009; 28: 667.
256. Castel MA, Pérez-Villa F, Roig E, et al. Heart transplantation in an HIV-1-infected patient with ischemic cardiomyopathy and severe pulmonary hypertension. Rev Esp Cardiol 2011; 64: 1065.
257. Castel MA, Pérez-Villa F, Miró JM. Heart transplantation in HIVinfected patients: More cases in Europe. J Heart Lung Transplant 2011; 30: 1418.
258. Boignard A, Blanc M, Chavanon O. High-urgency priority heart transplantation in HIV-positive patients on life support: Breaking barriers? J Heart Lung Transplant 2011; 30: 968.
259. Frassetto LA, Browne M, Cheng A, et al. Immunosuppressant pharmacokinetics and dosing modifications in HIV-1 infected liver and kidney transplant recipients. Am J Transplant 2007; 7: 2816.
260. Brucato A, Colombo T, Bonacina E, et al. Fulminant myocarditis during HIV seroconversion: Recovery with temporary left ventricular mechanical assistance. Ital Heart J 2004; 5: 228.
261. Fieno DS, Czer LS, Schwarz ER, et al. Left ventricular assist device placement in a patient with end-stage heart failure and human immunodeficiency virus. Interact Cardiovasc Thorac Surg 2009; 9: 919.
262. Mehmood S, Blais D, Martin S, et al. Heartmate XVE destination therapy for end-stage heart failure in a patient with human immunodeficiency virus. Interact Cardiovasc Thorac Surg 2009; 9: 909.
263. Sims DB, Uriel N, González-Costello J, et al. Human immunodeficiency virus infection and left ventricular assist devices: A case series. J Heart Lung Transplant 2011; 30: 1060.
264. Bertani A, Grossi P, Vitulo P, et al. Successful lung transplantation in an HIV- and HBV-positive patient with cystic fibrosis. Am J Transplant 2009; 9: 2190.
265. Blumberg EA, Stock P; the AST Infectious Diseases Community of Practice. Solid Organ Transplantation in the HIV Infected Patient. Am J Transplant 2009; 9(suppl 4): S131.
266. Freudenberger RS, Boruchoff SE, Anderson MB. Policies of U.S. heart transplant programs regarding transplantation ofhumanimmunodeficiencypositive patients. J Heart Lung Transplant 2004; 23: 785. (Pubitemid 38721455)
267. Roland ME, Havlir DV. Responding to organ failure in HIV-infected patients. N Engl J Med 2003; 348: 2279.
268. Jahangiri B, Haddad H. Cardiac transplantation in HIV-positive patients: Are we there yet? J Heart Lung Transplant 2007; 26: 103.
269. Armstrong GL, Alter MJ, McQuillan GM, et al. The past incidence of hepatitis C virus infection: Implications for the future burden of chronic liver disease in the United States. Hepatology 2000; 31: 777.
270. Maheshwari A, Ray S, Thuluvath PJ. Acute hepatitis C. Lancet 2008; 372: 321.
271. Westin J, Nordlinder H, Lagging M, et al. Steatosis accelerates fibrosis development over time in hepatitis C virus genotype 3 infected patients. J Hepatol 2002; 37: 837.
272. Hofer H, Bankl HC, Wrba F, et al. Hepatocellular fat accumulation and low serum cholesterol in patients infected with HCV-3a. Am J Gastroenterol 2002; 93: 2880.
273. Bochud PY, Cai T, Overbeck K, et al.; on behalf of the Swiss Hepatitis C Cohort Study Group. Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C. J Hepatol 2009; 51: 655.
274. Ghany MG, Strader DB, Thomas KL, et al. Diagnosis, management, and treatment of Hepatitis C: An update. Hepatology 2009; 49: 1335.
275. Tohme RA, Holmberg SD. Is sexual contact a major mode of hepatitis C virus transmission? Hepatology 2010; 4: 1497.
276. Williams MJ, Lawson A, Neal KR, et al.; on behalf of the Trent HCV Group. Autoantibodies in chronic hepatitis C virus infection and their association with disease profile. J Viral Hepatitis 2009; 16: 325.
277. McHutchison JG, Lawitz EJ, Shiffman ML, et al. IDEAL Study Team Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009; 361: 580.
278. Swain MG, Lai MY, Shiffman ML, et al. A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin. Gastroenterology 2010; 139: 1593.
279. Jensen DM, Marcellin P, Freilich B, et al. Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon-alpha2b: A randomized trial. Ann Intern Med 2009; 150: 528.
280. Clark PJ, Thompson AJ, McHutchison JG. IL28B genomic-based treatment paradigms for patients with chronic hepatitis C infection: The future of personalizedHCVtherapies.AmJ Gastroenterol 2011; 106: 38.
281. Asselah T, Marcellin P. New direct-acting antivirals' combination for the treatment of chronic hepatitis C. Liver Int 2011; 31(suppl 1): 68.
282. Italian Association for the Study of the Liver; Italian Society of Infectious, Tropical Diseases; Italian Society for the Study of Sexually Transmitted Diseases. Practice guidelines for the treatment of hepatitis C: recommendations from an AISF/SIMIT/SIMAST Expert Opinion Meeting. Dig Liver Dis 2010; 42: 81.
283. Liu CJ, Chuang WL, Lee CM, et al. Peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses. Gastroenterology 2009; 136: 496.
284. Huang JF, Yu ML, Huang CF, et al. The efficacy and safety of pegylated interferon plus ribavirin combination therapy in chronic hepatitis c patients with hepatocellular carcinoma post curative therapies-a multicenter prospective trial. J Hepatol 2011; 54: 219.
285. Vezali E, Aghemo A, Colombo M. A review of the treatment of chronic hepatitis C virus infection in cirrhosis. Clin Ther 2010; 32: 2117.
286. Liu CH, Kao JH. Treatment of hepatitis C virus infection in patients with end-stage renal disease. J Gastroenterol Hepatol 2011; 26: 228.
287. Wedemeyer H, Pethig K, Wagner D, et al. Long-term outcome of chronic hepatitis B in heart transplant recipients. Transplantation 1998; 66: 1347.
288. Fagiuoli S, Minniti F, Pevere S, et al. HBV and HCV infections in heart transplant recipients. J Heart Lung Transplant 2001; 20: 718.
289. Potthoff A, Tillmann HL, Bara C, et al. Improved outcome of chronic hepatitis B after heart transplantation by long-term antiviral therapy. J Viral Hepat 2006; 13: 734.
290. Cadranel JF, Grippon P, Lunel F, et al. Chronic liver dysfunction in heart transplant recipients, with special reference to viral B, C, and non-A, non-B, non-C hepatitis A retrospective study in 80 patients with follow-up of 60 months. Transplantation 1991; 52: 645.
291. Fagiuoli S, Pevere S, Minniti F, et al. Natural leukocyte interferon alfa for the treatment of chronic viral hepatitis in heart transplant recipients. Transplantation 2003; 75: 982.
292. Hosenpud JD, Pamidi SR, Fiol BS, et al. Outcomes in patients who are hepatitis B surface antigen-positive before transplantation: An analysis and study using the joint ISHLT/UNOS thoracic registry. J Heart Lung Transplant 2000; 19: 781.
293. Aroldi A, Lampertico P, Montagnino G, et al. Natural history of hepatitis B and C in renal allograft recipients. Transplantation 2005; 79: 1132.
294. Fong TL, Bunnapradist S, Jordan SC, et al. Impact of hepatitis B core antibody status on outcomes of cadaveric renal transplantation: Analysis of United Network of Organ Sharing database between 1994 and 1999. Transplantation 2002; 73: 85.
295. Yap DY, Tang CS, Yung S, et al. Long-term outcome of renal transplant recipients with chronic hepatitis B INFECTION-Impact of antiviral treatments. Transplantation 2010; 90: 325.
296. Grossi P, Dalla Gasperina D, Furione M, et al. Lamivudine treatment for HBV infection following thoracic organ transplantation. Transplant Proc 2001; 33: 1576.
297. Shitrit AB, Kramer MR, Bakal I, et al. Lamivudine prophylaxis for hepatitis B virus infection after lung transplantation. Ann Thorac Surg 2006; 81: 1851.
298. Samuel D, Muller R, Alexander G, et al. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 1993; 329: 1842.
299. Fagiuoli S, Leandro G, Bellati G, et al. Liver transplantation in Italy: Preliminary 10-year report. The Monotematica Aisf-Olt Study Group. Ital J Gastroenterol 1996; 28: 343.
300. Marzano A, Gaia S, Ghisetti V, et al. Viral load at the time of liver transplantation and risk of hepatitis B virus recurrence. Liver Transpl 2005; 11: 402.
301. Afonso RC, Hidalgo R, Paes AT, et al. Impact of cumulative risk factors for expanded criteria donors on early survival after liver transplantation. Transplant Proc 2008; 40: 800.
302. Perrillo RP, Eason JD. The use of HBsAg-positive organ donors: Far more than meets the eye? Liver Transpl 2005; 11: 875.
303. Gonzalez-Peralta RP, Andres JM, Tung FY, et al. Transplantation of a hepatitis B surface antigen-positive donor liver into a hepatitis B virusnegative recipient. Transplantation 1994; 58: 114.
304. Ho JK, Harrigan PR, Sherlock CH, et al. Utilization of a liver allograft from a hepatitis B surface antigen positive donor. Transplantation 2006; 81: 129.
305. Hwang S, Lee SG, Park KM, et al. Five-year follow-up of a hepatitis B virus-positive recipient of hepatitis B surface antigen-positive living donor liver graft. Liver Transpl 2006; 12: 993.
306. Soejima Y, Shimada M, Taketomi A, et al. Successful living donor liver transplantation using a graft from a hepatitis B surface antigen-positive donor. Liver Int 2007; 27: 1282.
307. Franchello A, Ghisetti V, Marzano A, et al. Transplantation of hepatitis B surface antigen-positive livers into hepatitis B virus-positive recipients and the role of hepatitis delta coinfection. Liver Transpl 2005; 11: 922.
308. Loggi E, Bihl F, Chisholm JV III, et al. Anti-HBs re-seroconversion after liver transplantation in a patient with past HBV infection receiving a HBsAg positive graft. J Hepatol 2009; 50: 625.
309. Saab S, Desai S, Tsaoi D, et al. Posttrasnplantation Hepatitis B prophylaxis with combination oral nucleoside and nucleotide analog therapy. Am J Transplant 2011; 11: 511.
310. Brunetto MR, Oliveri F, Colombatto P, et al. Use of hepatitis B surface antigen serum levels help to distinguish active from inactive hepatitis B virus genotype D carriers. Gastroenterology 2010; 139: 483.
311. Fishman JA. Infection in solid-organ transplant recipients. N Engl J Med 2007; 357: 2601.
312. Singh N, Wagener MM, Obman A, et al. Bacteremias in liver transplant recipients: Shift toward gram-negative bacteria as predominant pathogens. Liver Transpl 2004; 10: 844.
313. Rodriguez C, Munoz P, Rodriguez-Creixems M, et al. Bloodstream infections among heart transplant recipients. Transplantation 2006; 81: 384.
314. Al-Hasan MN, Razonable RR, Eckel-Passow JE, et al. Incidence rate and outcome of Gram-negative bloodstream infection in solid organ transplant recipients. Am J Transplant 2009; 9: 835.
315. Mrzljak A, Peric Z, Kovacevic V, et al. Rising problem of multidrugresistant gram-negative bacteria causing bloodstream infections after liver transplantation: How should we handle the issue? Liver Transpl 2010; 16: 1217.
316. Husain S, Chan KM, Palmer SM, et al. Bacteraemia in lung transplant recipients in the current era. Am J Transplant 2006; 6: 3000.
317. Bush K. Bench-to-bedside review: The role of beta-lactamases in antibiotic-resistant Gram-negative infections. Crit Care 2010; 14: 224.
318. European Centre for Disease Prevention and Control. Antimicrobial resistance surveillance in Europe 2009. Annual Report of the European Antimicrobial Resistance Surveillance Network (EARS-Net). Stockholm: ECDC; 2010. Available at: http://www.ecdc.europa.eu/en/ publications/Publications/1011-SUR- annual-EARS-Net-2009.pdf. Accessed November 2011.
319. Lupei MI, Mann HJ, Beilman GJ, et al. Inadequate antibiotic therapy in solid organ transplant recipients is associated with a higher mortality rate. Surg Infect (Larchmt) 2010; 11: 33.
320. Rossolini GM, Mantengoli E, Docquier JD, et al. Epidemiology of infections caused by multiresistant gram-negatives: ESBLs, MBLs, panresistant strains. New Microbiol 2007; 30: 332.
321. Livermore DM. Has the era of untreatable infections arrived? J Antimicrob Chemother 2009; 64(suppl 1): i29.
322. Castanheira M, Mendes RE, Woosley LN, et al. Trends in carbapenemase producing Escherichia coli and Klebsiella spp. from Europe and the Americas: Report from the SENTRY antimicrobial surveillance programme (2007- 09). J Antimicrob Chemother 2011; 66: 1409.
323. Nordmann P, Cuzon G, Naas T. The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria. Lancet Infect Dis 2009; 9: 228.
324. Poirel L, Naas T, Nordmann P. Diversity, epidemiology, and genetics of class D beta-lactamases. Antimicrob Agents Chemother 2010; 54: 24.
325. Cornaglia G, Giamarellou H, Rossolini GM. Metallo-β-lactamases: A last frontier for β-lactams? Lancet Infect Dis 2011; 11: 381.
326. Detection of the KPC gene in Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Acinetobacter baumannii during a PCRbased nosocomial surveillance study in Puerto Rico.Robledo IE, Aquino EE, Vázquez GJ. Antimicrob Agents Chemother 2011; 55: 2968.
327. Kitchel B, Rasheed JK, Patel JB, et al. Molecular epidemiology of KPCproducing Klebsiella pneumoniae isolates in the United States: Clonal expansion of multilocus sequence type 258. Antimicrob Agents Chemother 2009; 53: 3365.
328. Cuzon G, Naas T, Truong H, et al. Worldwide diversity of Klebsiella pneumoniae that produce beta-lactamase blaKPC-2 gene. Emerg Infect Dis 2010; 16: 1349.
329. Woodford N, Turton JF, Livermore DM. Multiresistant gram-negative bacteria: The role of high-risk clones in the dissemination of antibiotic resistance. FEMS Microbiol Rev 2011; 35: 736.
330. Kontopoulou K, Protonotariou E, Vasilakos K, et al. Hospital outbreak caused by Klebsiella pneumoniae producing KPC-2 beta-lactamase resistant to colistin. J Hosp Infect 2010; 76: 70.
331. Mezzatesta ML, Gona F, Caio C, et al. Outbreak of KPC-3-producing, and colistin-resistant, Klebsiella pneumoniae infections in two Sicilian hospitals. Clin Microbiol Infect 2011; 17: 1444.
332. Borer A, Saidel-Odes L, Riesenberg K, et al. Attributable mortality rate for carbapenem-resistant Klebsiella pneumoniae bacteremia. Infect Control Hosp Epidemiol 2009; 30: 972.
333. A.K.C. Brassinga, B. Wispelwey et al. Fatal cross infection by carbapenem resistant Klebsiella in two liver transplant recipients. Transpl Infect Dis 2009; 11: 257.
334. Higgins PG, Dammhayn C, Hackel M, et al. Global spread of carbapenem resistant Acinetobacter baumannii. J Antimicrob Chemother 2010; 65: 233.
335. Garnacho-Montero J, Amaya-Villar R. Multiresistant Acinetobacter baumannii infections: Epidemiology and management. Curr Opin Infect Dis 2010; 23: 332.
336. Neonakis IK, Spandidos DA, Petinaki E. Confronting multidrug-resistant Acinetobacter baumannii: A review. Int J Antimicrob Agents 2011; 37: 102.
337. Reddy P, Zembower TR, Ison MG, et al. Carbapenem-resistant Acinetobacter baumannii infections after organ transplantation. Transpl Infect Dis 2010; 12: 87.
338. Biancofiore G, Tascini C, Bisà M, et al. Colistin, meropenem and rifampin in a combination therapy for multi-drug-resistant Acinetobacter baumannii multifocal infection. A case report. Minerva Anestesiol 2007; 73: 181.
339. Pachón-Ibáñez ME, Docobo-Pérez F, Ló pez-Rojas R, et al. Efficacy of rifampin and its combinations with imipenem, sulbactam, and colistin in experimental models of infection caused by imipenem-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 2010; 54: 1165.
340. Grundmann H, Livermore DM, Giske CG, et al. Carbapenem-nonsusceptible Enterobacteriaceae in Europe: Conclusions from a meeting of national experts. Euro Surveill 2010; 15 pii: 19711.
341. Moellering RC Jr. NDM-1 a cause for worldwide concern.NEngl J Med 2010; 363: 2377.
342. D'Andrea MM, Venturelli C, Giani T, et al. Persistent carriage and infection by multidrug-resistant Escherichia coli ST405 producing NDM-1 carbapenemase: Report on the First Italian cases. J Clin Microbiol 2011; 49: 2755.
343. Pappas PG, Alexander BD, Andes DR, et al. Invasive fungal infections among organ transplant recipients: Results of the Transplant Associated Infection Surveillance Network (TRANSNET). Clin Inf Dis 2010; 50: 1101.
344. Mayr A, Aigner M, Lass-Florl C, et al. Anidulafungin for the treatment of invasive candidiasis. Clin Microbiol Infect 2011; 17(suppl 1): 1.
345. Pappas PG, Andesb D, Schusterc M, et al. Invasive fungal infections in low-risk liver transplant recipients: A multi-center prospective observational study. Am J Transpl 2006; 6: 386.
346. Husain S, Tollemar J, Dominguez EA, et al. Changes in the spectrum and risk factors for invasive candidiasis in liver transplant recipients: Prospective, multicenter, case-controlled study. Transplantation 2003; 75: 2023.
347. Kullberg BJ, Verweij PE, Akova M, et al. European expert opinion on the management of invasive candidiasis in adults. Clin Microbiol Infect 2011; 17(suppl 5): 1.
348. Grossi PA, Dalla Gasperina D, Barchiesi F, et al. Italian Guidelines for diagnosis, prevention, and treatment of invasive fungal infections in solid organ transplant recipients. Transpl Proc 2011; 43: 2463.
349. Guery BP, Arendrup MC, Auzinger G, et al. Management of invasive candidiasis and candidemia in adult non-neutropenic intensive care unit patients: Part II. Intens Care Med 2009; 35: 206.
350. Baddley JW, Andes DR, Marr KA, et al. Factors associated with mortality in transplant patients with invasive aspergillosis. Clin Inf Dis 2010; 50: 1559.